 UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical stage immuno-oncology company focused on developing its proprietary GammabodyTM platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference. 